Compugen Investor Relations Material
Latest events
Q2 2025
Compugen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Compugen Ltd
Access all reports
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on immuno-oncology and autoimmune diseases. The company leverages a predictive computational discovery platform to identify novel drug targets and develop therapeutic products. Its pipeline includes a range of products in clinical trials, such as COM701 and COM902, which target various cancers including non-small cell lung cancer and head and neck squamous cell carcinoma. The company is headquartered in Holon, Israel, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CGEN
Country
🇺🇸 United States